Articles On Imagion Biosystems (ASX:IBX)
| Title | Source | Codes | Date |
|---|---|---|---|
|
Imagion poised to accelerate Magsense progress
Through the filing of a Pre-Submission with the U.S. Food and Drug Administration (FDA), MedTech company Imagion Biosystems (ASX:IBX) has taken its first step towards gaining approval to commence its first-in-human study into its non-invasi... |
FinFeed | IBX | 6 years ago |
|
Imagion Biosystems files for first-in-human study
Imagion Biosystems (ASX:IBX) says it has filed pre-submission with the US Food and Drug Administration (FDA), the first step in gaining approval to commence its first-in-human study. |
BiotechDispatch | IBX | 6 years ago |
|
Health: Orthocell’s technology could be even more powerful than first thought
Remember Orthocell (ASX: OCC), that company gained 377 per cent in a day when it showed Cel-Gro helped patients with nerve damage regain sensation? It could be even more powerful than it showed then. While indeed, the trial showed it helpe... |
Stockhead | IBX | 6 years ago |
|
Breakthrough designation for Imagion test
Imagion Biosystems (ASX:IBX) has received notification from the FDA's Center for Devices and Radiological Health (CDRH) that its MagSense System and Test for staging HER2 breast cancer has qualified for and been granted designation... |
BiotechDispatch | IBX | 6 years ago |
|
Is it a good or bad thing if a small cap’s enterprise value exceeds its market cap?
At Stockhead, we tend to judge a company’s size by its market capitalisation. But a company’s enterprise value may be substantially greater – is this good or bad? In short, it depends. Using a base of $500 million, Stockhead has recapped s... |
Stockhead | IBX | 6 years ago |
|
Imagion Biosystems has breast cancer technology qualified as a breakthrough device
The MagSense test aims to eliminate the unnecessary surgeries and concomitant morbidity resulting from the standard of care biopsy procedure. |
Proactive Investors | IBX | 6 years ago |
|
Tech: Imagion Biosystems scores breakthrough with US regulators; shares go ballistic
Medical tech company Imagion Biosystems (ASX: IBX) has scored a key breakthrough in the development of its breast cancer-detection treatment. The company’s MagSense technology is an upgrade on existing diagnostic imaging uses tiny nanoparti... |
Stockhead | IBX | 6 years ago |
|
Imagion Biosystems receives FDA breakthrough designation for breast cancer detection device
Imagion Biosystems (ASX: IBX) has received notification from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) that the MagSense System and Test for staging HER2 breast cancer had qualified for... |
SmallCaps | IBX | 6 years ago |
|
Top 10 at 10: These ASX stocks are in the groove this morning
Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte... |
Stockhead | IBX | 6 years ago |
|
Escrow Watch: Who’s unleashing stock into the ASX this fortnight?
Want to know when shares are coming out of escrow? We’ve been keeping tabs, so you don’t have to. Every two weeks, Stockhead takes a look at the small cap companies that are releasing shares that have been locked away in escrow. Escrow refe... |
Stockhead | IBX | 6 years ago |